New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT07231458
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in 27 people with advanced solid tumors who have no standard treatment options left. The main goal is to check safety and find the right dose, while also looking for any signs that the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABX-001 (an experimental drug) and pembrolizumab (an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 27 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)
RECRUITINGBerlin, 12200, Germany
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
The START Center for Cancer Care - CIOCC
RECRUITINGMadrid, 28050, Spain
-
Universitaetsklinikum Tuebingen
RECRUITINGTübingen, 72076, Germany
-
Vall d'Hebron Institut d'Oncologia
RECRUITINGBarcelona, 08035, Spain